Application of naringenin and naringenin composition in preparation of medicine for treating or preventing toxoplasmosis

A technology of toxoplasmosis and naringenin, which is applied in the preparation of drugs for the treatment or prevention of toxoplasmosis, in the field of naringenin, achieves the effects of low toxicity, convenient treatment or prevention, and prevention of toxoplasmosis

Pending Publication Date: 2021-05-28
LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have shown that naringenin has an active effect on protozoa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of naringenin and naringenin composition in preparation of medicine for treating or preventing toxoplasmosis
  • Application of naringenin and naringenin composition in preparation of medicine for treating or preventing toxoplasmosis
  • Application of naringenin and naringenin composition in preparation of medicine for treating or preventing toxoplasmosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Toxicity of naringenin to Vero cells

[0024] 1. Experimental process

[0025] The CCK-8 method was used to determine the toxicity of naringenin to Vero cells.

[0026] Adjust the concentration of Vero cells to 1 x 10 5 cells / mL, inoculate them in 96-well plates, and after culturing for 12 hours, add different concentrations of naringenin solutions respectively, and use 0.25% DMSO as the control group, and use pure medium as the blank group. After culturing for 24 hours, CCK-8 reagent was added, and after acting for 1 hour, the optical density OD value of each well was measured in a 450 nm microplate reader. Calculate the survival rate of Vero cells according to the following formula, and draw the curve and calculate the IC 50 value.

[0027] Cell viability (%) = (OD 试验组 -OD 空白组 ) / (OD 对照组 -OD 空白组 )×100%

[0028] 2. Experimental results

[0029] The above-mentioned naringenin solutions of different concentrations are calculated on the survival rate of...

Embodiment 2

[0033] The inhibitory effect of embodiment two naringenin to Toxoplasma gondii

[0034] 1. Experimental process

[0035] Toxoplasma gondii RH-2F strain expressing β-galactosidase was used for growth inhibition assay.

[0036] Harvest fresh and vigorous Toxoplasma gondii RH-2F tachyzoites from Vero cells, inoculate them in 96-well plates, count on a hemocytometer, and adjust the concentration of Toxoplasma gondii RH-2F tachyzoites to 1×10 5 individual / mL. Different concentrations of naringenin solutions were prepared and added to 96-well plates respectively, with 0.25% DMSO as the control group and pure medium as the blank group. After 12 hours of incubation, add As for the detection reagent, after acting for 30 minutes, detect the luminescence value in a photometer. Calculate the survival rate of Toxoplasma gondii RH-2F tachyzoites, draw the curve and calculate the IC 50 value.

[0037] 2. Experimental results

[0038] The above-mentioned naringenin solutions of differ...

Embodiment 3

[0044] The anti-proliferation effect of embodiment three naringenin on intracellular Toxoplasma gondii type I strain (RH)

[0045] 1. Experimental process

[0046] Will 1×10 5 RH tachyzoites / mL of the Toxoplasma gondii type I strain were inoculated in a monolayer of Vero cells in a 12-well plate. After invading for 4 hours, a naringenin solution with a concentration of 60 μg / mL was added and mixed with 0.25% DMSO As the negative control group, 10 μg / mL pyrimethamine was used as the positive control group for 24 h and 48 h, then fixed with 4% paraformaldehyde, antigen retrieval, blocked with 10% goat serum, permeabilized with 0.2% Triton X-100, Toxoplasma was labeled with rabbit anti-toxoplasma polyclonal antibody, the secondary antibody was goat anti-rabbit IgG H&L, and the nuclei were stained with DAPI. After staining and mounting, the slides were observed and photographed under a confocal microscope.

[0047] 2. Experimental results

[0048] attached image 3 It is the pi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of naringenin and pharmaceutically acceptable salts thereof in preparation of drugs for treating or preventing toxoplasmosis. The effective concentration of the naringenin is 50-120 [mu]g/mL. The invention also discloses application of a pharmaceutical composition containing naringenin and pharmaceutically acceptable salts thereof in preparation of drugs for treating or preventing toxoplasmosis. According to the application disclosed by the invention, the naringenin has a good effect of treating or preventing toxoplasmosis by utilizing the inhibition and anti-proliferation effects of the naringenin on toxoplasma gondii and the anti-invasion effect of the naringenin on extracellular toxoplasma gondii, and the research on the toxicity of the naringenin on Vero cells finds that the naringenin is small in toxicity, safe and reliable. Therefore, the naringenin and the naringenin composition have obvious application effects and small toxic and side effects in preparation of drugs for treating or preventing toxoplasmosis.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the application of naringenin and its composition in the preparation of medicines for treating or preventing toxoplasmosis. Background technique [0002] Toxoplasma belongs to Apicomplexa, Sporozoa, Coccidia, Eucoccidia, Eimeria, Toxoplasma, Toxoplasma. There is only one species under the genus Toxoplasma, Toxoplasmagondii, commonly known as Toxoplasma gondii. However, according to different regions, different hosts, different virulence, life history and development time, etc., it can be divided into three different genotypes, type Ⅰ (RH and GT-1 strains), type Ⅱ (ME49 and PRU strain) and type III (CEP and VEG strains). Toxoplasma gondii is an intracellular parasitic protozoan, which can infect all warm-blooded animals including humans, and even some cold-blooded animals, and can parasitize in all nucleated cells of the animal body. Toxoplasmosis is divided into congenital t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P33/02A23K20/121
CPCA61K31/352A61P33/02A23K20/121
Inventor 张继瑜邱燕华翟斌涛魏小娟程富胜王玮玮杨枭荣
Owner LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap